Apoptotic cells induce tolerance through TRAIL-expressing CD8+ regulatory T cells
Apoptotic cells induce tolerance through TRAIL-expressing CD8+ regulatory T cells
批准号:
7892840
负责人:
Thomas S Griffith
金额:
$37.19万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-15 至 2011-07-31
关键词:
AdjuvantAnimalsAntigensApoptoticAutoimmune DiseasesAutoimmunityBiological ModelsBloodCD8B1 geneCell DeathCellsCellular ImmunityCessation of lifeComplexDataEyeFailureGenerationsGoalsGraft RejectionImmuneImmune ToleranceImmune responseImmune systemImmunityImmunizationImmunotherapeutic agentImpairmentIndividualInduction of ApoptosisInflammatoryInflammatory ResponseInjection of therapeutic agentIntentionIntravenousMaintenanceMediatingMediator of activation proteinModelingMolecularMusOrganPeripheralPopulationPositioning AttributeProtocols documentationPublishingReactionReagentRegulationReportingResearchResistanceRoleRouteSelf ToleranceSiteSplenocyteSystemT-LymphocyteTNF-related apoptosis-inducing ligandTechnologyTissuesTransplantationanterior chamberbasechronic autoimmune diseaseexpectationinnovationinterestnovel markerpreventresponsetherapy developmenttumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The host response to pathogenic insults involves complex inflammatory responses and cellular immune reactions,
such that the decision to generate protective immunity or tolerance often depends on the context in which T cells first
encounter antigen (Ag). While the induction of immunological tolerance was first described almost 100 years ago, the idea
that tolerance could be actively mediated by T cells and transferred to na¿ve recipients was not proposed until the 1970's.
Regulatory T cells (Treg) are critical mediators of immune tolerance, and understanding the mechanisms that govern their
generation and function has enormous bearing on the development of therapies for T cell-mediated autoimmune diseases
and chronic transplant rejection. There has been a renewed interest in T cell-mediated immune regulation over the last
decade, with the vast majority of research focused primarily on CD4+ Treg. However, the early reports detailing immune
tolerance described the activity of CD8+ Treg, and there is still very little known regarding how CD8+ Treg develop and
function. Studies on T cell tolerance have shown that Ag injection into the anterior chamber (AC) of the eye induces an
immune deviation (called anterior chamber associated immune deviation, ACAID) - characterized by the induction of an
Ab response, with simultaneous impairment (or tolerance) of cell-mediated immunity. Another key feature of ACAID is that
the tolerance is "infectious", i.e. it can be transferred from a tolerant individual to a na¿ve recipient. In many ways, the
immunological response to Ag presented via the AC of the eye is very similar to the response induced after intravenous
(i.v.) immunization of soluble Ag: immunological tolerance upon challenge, ability to transfer tolerance to na¿ve animals
with CD8+ T cells obtained from tolerized mice, necessity for the apoptotic death of Ag-coupled cells to induce tolerance,
and, based on our published and preliminary data, the key role of TNF-related apoptosis-inducing ligand (TRAIL) in the
establishment of tolerance.
The tolerance observed in both of these model systems is not simply due to the failure to prime, but results from the
generation of CD8+ Treg. To further investigate the hypothesis that the tolerance induced in both of these models is
mediated by TRAIL-expressing CD8+ Treg, we propose the following Specific Aims: Aim 1 - Determine the impact of
peripheral deletion of antigen-specific T cells on the induction of tolerance by TRAIL-expressing CD8+ Treg, Aim 2 -
Determine the mechanism behind the inability of activated apoptotic cells to induce tolerance, compared to na¿ve
apoptotic cells, when injected intravenously, and Aim 3 - Determine the role of TRAIL in the ability of antigen
administered through the AC to stimulate antigen-specific regulatory CD8+ Treg that mediate systemic tolerance. As
interest in TRAIL has grown since its initial discovery as a tumoricidal molecule, TRAIL is now known to possess functions
that go beyond tumor surveillance. There has also been a renewed interest in T cell-mediated suppression with the
availability of new reagents and technology. Thus, our proposal will investigate the role of TRAIL-expressing CD8+ Treg in
the induction and maintenance of immunological tolerance using 2 classical tolerance models, with the intention of
applying our findings in the treatment of autoimmunity or increase transplant survival.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BLRD Research Career Scientist Award Application
-
批准号:10582394
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:Thomas S Griffith
-
依托单位:
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology
-
批准号:10257687
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
CD4 T cell dysfunction and reprogramming during sepsis
-
批准号:10633073
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
Exploiting microbial exposure to study the immune response to uropathogenic E. coli
-
批准号:10413143
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology
-
批准号:10512750
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
Exploiting microbial exposure to study the immune response to uropathogenic E. coli
-
批准号:10237569
-
项目类别:
-
资助金额:$23.24万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
CD4 T cell dysfunction and reprogramming during sepsis
-
批准号:10400169
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
Alterations in CD4 T cells during sepsis
-
批准号:9101373
-
项目类别:
-
资助金额:$31.59万
-
财政年份:2016
-
负责人:Thomas S Griffith
-
依托单位:
Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis
-
批准号:10084212
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Suppression of T cell immunity during sepsis
-
批准号:8601255
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Suppression of T cell immunity during sepsis
-
批准号:8237299
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Using microbially-experienced mice to study the innate immune response in sepsis
-
批准号:10655287
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Using microbially-experienced mice to study the innate immune response in sepsis
-
批准号:10367761
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
TRAIL: A MECHANISM FOR BCG-INDUCED ANTI-TUMOR ACTIVITY IN BLADDER CANCER
-
批准号:7604865
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2007
-
负责人:Thomas S Griffith
-
依托单位:
Recombinant Immunotherapy for Renal Cell Carcinoma
-
批准号:7227055
-
项目类别:
-
资助金额:$25.8万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
-
批准号:8255342
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
-
批准号:7851372
-
项目类别:
-
资助金额:$26.88万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
Recombinant Immunotherapy for Renal Cell Carcinoma
-
批准号:6901940
-
项目类别:
-
资助金额:$27.21万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
Recombinant Immunotherapy for Renal Cell Carcinoma
-
批准号:6816995
-
项目类别:
-
资助金额:$27.21万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
-
批准号:8484212
-
项目类别:
-
资助金额:$24.29万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
海外基金